Clinical Trials Logo

Pigmentation Disorders clinical trials

View clinical trials related to Pigmentation Disorders.

Filter by:

NCT ID: NCT04202419 Completed - Clinical trials for Pigmented Skin Lesion

Nonablative Fractional Diode Laser for Treatment of Pigmented Lesions

Start date: January 9, 2020
Phase: N/A
Study type: Interventional

This study is being conducted to evaluate the safety and efficacy of a fractional diode laser for treatment of pigmented lesions such as, but not limited to lentigos (age spots), solar lentigos (sunspots), and ephelides (freckles).

NCT ID: NCT03530787 Completed - Microbiome Clinical Trials

Cosmetic Effects of Topical Acetyl Zingerone

Start date: December 11, 2017
Phase: N/A
Study type: Interventional

Cosmeceuticals are an emerging market within dermatology and the growth of natural products and derivatives of natural products has accelerated in use within the field. Here the investigators aimed to study the microbial and cosmetic effects of Synoxyl AZ, the trade name for topical acetyl zingerone (AZ), a novel compound designed based on Zingerone and curcumin.

NCT ID: NCT03421691 Completed - Photoaging Clinical Trials

A Single-Center Open-Label Study of 1064 nm for Nonablative Skin Rejuvenation

Start date: March 15, 2016
Phase: N/A
Study type: Interventional

The purpose of this investigation is to evaluate the safety and efficacy of the Cutera excel V Laser Genesis procedure utilizing the 1064nm laser for skin rejuvenation.

NCT ID: NCT03362138 Recruiting - Melanoma Clinical Trials

Artificial Intelligence-assisted Evaluation of Pigmented Skin Lesions

NNCD
Start date: December 6, 2017
Phase:
Study type: Observational

Malignant melanoma (MM) is a deadly cancer, claiming globally about 160000 new cases per year and 48000 deaths at a 1:28 lifetime incidence (2016). The golden standard, dermoscopy, enables Dermatologists to diagnose with a sensitivity of 40%, and a 8-12% specificity, approximately. Additional diagnostic abilities are restricted to devices which are either unproved or experimental. A new technology of Neuronal Network Clinical Decision Support (NNCD) was developed. It uses a dermoscopic imaging device and a camera able to capture an image. The photo is transferred to a Cloud Server and further analyzed by a trained classifier. Classifier training is aimed at a high accuracy diagnosis of Dysplastic Nevi (DN), Spitz Nevi and Malignant Melanoma detection with assistance from a Deep Neuronal Learning network (DLN). Diagnosis output is an excise or do not excise recommendation for pigmented skin lesions. A total of 80 subjects already referred to biopsy pigmented skin lesions will be examined by dermoscopy imaging in a non interventional study. Artificial Intelligence output results, as measured by 2 different dermoscopes, to be compared to ground truth biopsies, by either classifier decisions or a novel Modified Classifier Technology output decisions. Primary endpoints are sensitivity and specificity detection of the NNCD techniques. Secondary endpoints are the positive and negative prediction ratios of NNCD techniques.

NCT ID: NCT03233828 Terminated - Melanoma (Skin) Clinical Trials

Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2

IL-2
Start date: December 19, 2018
Phase: Phase 3
Study type: Interventional

This study is meant to assess the use of intralesional IL-2 to modulate the immunological response to suspected melanoma, or melanoma in situ, in an effort to increase lymphocyte infiltration and decrease disease metastasis. Patients that are clinically diagnosed with suspected Melanoma or Melanoma in situ will be assigned to either a treatment or control arm. The treatment group will be subjected to two intralesional IL-2 injections, whereas the control group will be subjected to two intralesional injections of saline. The proteomic and metabolomic profiles of both groups will be analyzed using urine and blood samples in an effort to assess the systemic immunological response, if any, to the treatment. Also, upon disease confirmation and staging by a qualified pathologist, lesions will be assessed for lymphocyte infiltration using immunohistochemical methods. This study will determine whether pre-treatment of IL-2 on lesions (clinically diagnosed as melanoma or melanoma in situ) is effective in generating an adaptive immune response, and whether that immune response may play a role in preventing disease metastasis.

NCT ID: NCT03022773 Recruiting - Skin Pigment Clinical Trials

Macular Pigment Measurements in Eye & Other Tissues

Start date: June 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to understand the role of nutrition and its effects on the eye and other tissues. The investigators propose to study this by validating and correlating various non-invasive measurement methods of carotenoid concentrations in the human eye and skin tissue. A secondary objective is to correlate blood levels of carotenoids on a sub-set of participants.

NCT ID: NCT02848742 Completed - Clinical trials for Pigmented Skin Lesion

Dermal Cryotherapy for Treatment of Pigmented Lesions

Start date: June 2016
Phase: N/A
Study type: Interventional

Study to evaluate the ability of the Dermal Cooling System to reduce pigmentation in benign pigmented lesions.

NCT ID: NCT02663921 Completed - Skin Disease Clinical Trials

Visible Light Study

Start date: September 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to learn more about the potential effects of visible light on the skin. More specifically, this study will examine whether an incandescent lamp (light bulb) or LED light bulb can cause skin to become darker. Investigators will determine the minimum threshold dose required to achieve immediate pigmentation darkening (IPD), persistent pigmentation darkening (PPD), and delayed tanning (DT) for Fitzpatrick skin types IV - VI utilizing two visible light sources.

NCT ID: NCT02635880 Completed - Clinical trials for Pigmented Skin Lesion of Suspected Benign Nature

A Clinical Evaluation of a Novel Multi-Wavelength Laser for Benign Pigmented Lesion Removal

Start date: September 2015
Phase: N/A
Study type: Interventional

To evaluate the safety and efficacy of an investigational version of the Cutera enlightenTM laser that offers multiple wavelengths for removal of benign pigmented lesions.

NCT ID: NCT02613325 Completed - Melanoma Clinical Trials

fPAM for the in Vivo Depth Measurement of Pigmented Lesions and Melanoma Depth

Start date: June 8, 2015
Phase: Phase 1
Study type: Interventional

The investigators propose the use of functional photoacoustic microscopy (fPAM) to evaluate both benign and malignant pigmented lesions for tumor depth. Through fPAM analysis followed by histological examination, the investigators anticipate that they will be able to non-invasively determine tumor depth of pigmented lesions (moles and melanoma). In melanoma, tumor depth (Breslow's depth) is not only an important prognostic indicator, but also directs surgical treatment. The ultimate goal is to develop a sensitive clinical tool that will allow non-surgical evaluation of pigmented lesions, which eventually, will aid in melanoma diagnosis and management - potentially an earlier and more definitive surgical management. In addition, the investigators propose to use the combination of fPAM and single-cell PAM to respectively image CTCs in trunk vessels and cuticle capillaries. Based on the investigators' murine models, the investigators anticipate that they will be able to differentiate CTCs from other blood cells and reliably calculate CTC concentration in a non-invasive manner. CTC concentration has been demonstrated to be a valuable indicator of a melanoma's metastatic potential and a potential tool in evaluating treatment efficacy. The ultimate goal is to develop a sensitive imaging device that will allow accurate evaluation of the risk of melanoma recurrence and metastases, that may facilitate treatment monitoring.